Suppr超能文献

台湾帕金森病患者的医疗利用情况及费用

Healthcare utilization and costs for patients with Parkinson's disease in Taiwan.

作者信息

Chen Kuan-Chen, Ku Li-Jung Elizabeth, Hu Ya-Hui, Sun Yu, Elbaz Alexis, Lee Pei-Chen

机构信息

Department of Health Care Management, National Taipei University of Nursing and Health Sciences, No. 365, Mingde Road, Peitou District, Taipei City, 112, Taiwan.

Department of Public Health, College of Medicine, National Cheng Kung University, No.1, University Road, Tainan City, 701, Taiwan.

出版信息

BMC Neurol. 2025 Jan 3;25(1):3. doi: 10.1186/s12883-024-03988-3.

Abstract

BACKGROUND

Parkinson's disease (PD) exerts a considerable burden on the elderly. Studies on long-term costs for Parkinson's disease patients in Taiwan are not available.

OBJECTIVES

This study aims to examine the medical resource utilization and medical costs including drug costs for PD patients in Taiwan over up to 15 years of follow-up.

METHODS

Incident PD patients and matched non-PD subjects were identified between 2003 and 2016 from the National Health Insurance (NHI) research database. Differences in annual healthcare utilization and costs between PD and non-PD subjects from 2003 to 2018 were predicted by generalized linear models. We performed analyses stratified by PD severity and also by age, gender, and duration of follow-up.

RESULTS

We identified 50,290 PD cases and 201,153 non-PD subjects. From the payer's perspective, the average total medical costs (drug costs) associated with PD and non-PD subjects were NT$631,080 (NT$222,810) and NT$480,880 (NT$140,120), respectively. Total medical and drug costs of PD after diagnosis remained high, from NT$138,487 per patient in the first year following diagnosis up to NT$154,676 per patient at year 15. The largest components of costs were for outpatient care (55% of total medical costs), and total drugs cost (35% of total medical costs). Patients with severe PD incurred higher total medical costs compared to those with moderate or mild PD, with outpatient and inpatient costs as well as drug costs rising with disease severity.

CONCLUSIONS

This is the first study of its kind in Taiwan that comprehensively analyzes long-term healthcare utilization and costs among PD patients. PD imposes a significant economic burden in Taiwan, with medical (drug) costs being 1.31 (1.59) times that of non-PD individuals and costs increasing substantially with PD severity. Our findings can aid health policymakers in understanding the healthcare needs and medical costs of PD patients, supporting effective policy formulation.

摘要

背景

帕金森病(PD)给老年人带来了相当大的负担。台湾地区关于帕金森病患者长期费用的研究尚属空白。

目的

本研究旨在调查台湾地区帕金森病患者长达15年随访期内的医疗资源利用情况及医疗费用,包括药物费用。

方法

2003年至2016年期间,从国民健康保险(NHI)研究数据库中识别出帕金森病新发病例及匹配的非帕金森病受试者。采用广义线性模型预测2003年至2018年期间帕金森病患者与非帕金森病受试者年度医疗利用和费用的差异。我们按帕金森病严重程度以及年龄、性别和随访时间进行分层分析。

结果

我们识别出50290例帕金森病病例和201153名非帕金森病受试者。从支付方的角度来看,帕金森病患者与非帕金森病受试者的平均总医疗费用(药物费用)分别为新台币631080元(新台币222810元)和新台币480880元(新台币140120元)。帕金森病患者确诊后的总医疗费用和药物费用一直居高不下,从确诊后第一年的人均138487新台币到第15年的人均154676新台币。费用的最大组成部分是门诊护理(占总医疗费用的55%)和总药物费用(占总医疗费用的35%)。与中度或轻度帕金森病患者相比,重度帕金森病患者的总医疗费用更高,门诊和住院费用以及药物费用均随疾病严重程度上升。

结论

这是台湾地区首例全面分析帕金森病患者长期医疗利用和费用的此类研究。帕金森病在台湾地区造成了巨大的经济负担,医疗(药物)费用是非帕金森病个体的1.31(1.59)倍,且费用随帕金森病严重程度大幅增加。我们的研究结果有助于卫生政策制定者了解帕金森病患者的医疗需求和医疗费用,支持制定有效的政策。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dafc/11697947/f4c6fd5296fa/12883_2024_3988_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验